Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2025-10-21 00:00:00 ET · period of report 2025-10-20 · accession 0001193125-25-245106 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-21 | 2025-10-20 | FATE | Adawi Kamal | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
| D | 2025-10-21 | 2025-10-20 | FATE | Adawi Kamal | CFO | A - Grant | $0.00 | +375.0K | 375.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-20 | A | A | 75,000 | $0.00 | 75,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-10-20 | A | A | 375,000 | $0.00 | 375,000 | D | $1.54 · — to 2035-10-20 | 375,000 Common Stock | (F2) The option shall vest as to 25% of the underlying shares on October 20, 2026 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. |